logo-loader

Avalon GloboCare is seeking to tap the power of cells to fight cancer and coronavirus

Last updated: 09:48 18 Dec 2023 EST, First published: 16:00 14 Oct 2021 EDT

Snapshot

  • Avalon GloboCare engages ChtrBx to develop marketing launch plan for KetoAir
  • Avalon Globocare enters 'transformative' deal to acquire majority stake in Laboratory Services MSO
Cells

About the company

Avalon GloboCare Corp. is a leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative exosome technologies and cellular therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth, development, as well as competitiveness in both the domestic and global healthcare markets. Through its subsidiaries, namely GenExosome Technologies Inc. and Avactis Biosciences Inc., Avalon is establishing a leading role in the fields of exosome-based diagnostics ('liquid biopsy), cellular immunotherapy (including CAR-T/CAR-NK), and regenerative medicine.

How it is doing

18 Dec 2023

Avalon GloboCare Corp (NASDAQ:ALBT) announced that it has engaged ChtrBx, a marketing and branding company, to develop a marketing launch plan for KetoAir in North America, South America, the United Kingdom (UK) and the European Union (EU). 

The developer of innovative cell-based technology, cellular therapy and precision diagnostics said KetoAir functions as a companion diagnostic and monitoring device, combined with an artificial intelligence (AI) nutritionist consultation for ketogenic dietary management. 

"ChtrBx’s founder, Roy Edmondson, has been successful in orchestrating and launching multimedia campaigns globally for major brand names such as Levi Strauss & Co (NYSE:LEVI), Kodak, BestBuy, Rocawear, Absolut and many more," Avalon GloboCare CEO David Jin said in a statement. 

"We look forward to leveraging ChtrBx’s expertise to develop and execute an effective marketing program that we believe will yield positive results for KetoAir," he added.  

18 Oct 2023

Avalon GloboCare Corp (NASDAQ:ALBT) shares rose in early trade after it announced a partnership with medical device company Qi Diagnostics to co-develop international multi-center clinical studies for the DKAir breathalyzer device for the early detection of diabetic ketoacidosis (DKA).

Developed by Qi Diagnostics, the DKAir is a handheld breathalyzer that allows diabetic patients to detect the level of acetone in their breath.

04 Oct 2023

Avalon GloboCare Corp (NASDAQ:ALBT) has officially unveiled its KetoAir mobile application on the Apple App Store.

Coupled with an AI nutritionist and a nanosensor-based breathalyzer, KetoAir serves as a companion diagnostic and monitoring device for individuals practicing a ketogenic lifestyle

What management says

08 Nov 2022

 

Avalon GloboCare Corp (NASDAQ:AVCO) CEO Dr David Jin joins Proactive's Stephen Gunnion with details of a 'transformative' deal worth $31 million to acquire a 60% stake in Laboratory Services MSO and expand its focus on lab testing and services.

Jin tells Proactive that California-headquartered Laboratory Services has completed over 600,000 tests since inception and will add strong clinical synergies to the existing Avalon portfolio.

Avalon Globocare enters 'transformative' deal to acquire majority stake in...

  Avalon GloboCare Corp (NASDAQ:AVCO) CEO Dr David Jin joins Proactive's Stephen Gunnion with details of a 'transformative' deal worth $31 million to acquire a 60% stake in Laboratory Services MSO and expand its focus on lab testing and services. Jin tells Proactive that...

on 11/08/2022